# FDA 483 - Ajinomoto Althea, Inc. - January 16, 2023

Source: https://www.keypedia.com/records/483/ajinomoto-althea-inc/31d386f5-e5ea-4cf9-b563-54c74ade61ef

> FDA 483 for Ajinomoto Althea, Inc. on January 16, 2023. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ajinomoto Althea, Inc.
- Inspection Date: 2023-01-16
- Product Type: biologics
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
- Summary: Ajinomoto Althea, Inc. DBA Ajinomoto Bio-Pharma Services in San Diego, CA, was inspected and received a Form 483 with three observations. The inspection revealed deficiencies in quality oversight of validation activities, facility and equipment maintenance, and adherence to quality control unit procedures. These issues indicate a need for improved GMP compliance in critical manufacturing and laboratory operations.

## Related Documents

- [483 - 2023-01-16](https://www.keypedia.com/records/483/ajinomoto-althea-inc/14059599-d17b-4422-a4b2-70d7caea5b4e)
- [483 - 2025-05-09](https://www.keypedia.com/records/483/ajinomoto-althea-inc/460eb7ec-a1f2-489e-af6c-54a4f2adef31)
- [483 - 2023-02-09](https://www.keypedia.com/records/483/ajinomoto-althea-inc/580fc4cc-211e-489a-8466-337a0c433bff)
- [483 - 2019-08-07](https://www.keypedia.com/records/483/ajinomoto-althea-inc/f4a2b512-1b50-4605-a609-304be78baf30)
- [483 - 2019-08-07](https://www.keypedia.com/records/483/ajinomoto-althea-inc/3d93883f-f165-4823-9a81-b4dcd9f427e3)

## Related Officers

- [Consumer Safety Officer (Inspector)](https://www.keypedia.com/people/christopher-r-czajka/42defbf3-ea06-4090-8d51-7da2b07d9e84)
- [Investigator](https://www.keypedia.com/people/michael-r-shanks/dd24952b-4309-451e-afe8-f68892cd7bac)
- [Regulatory Scientist at FDA](https://www.keypedia.com/people/yi-wang/f5355ae0-ae28-452f-829a-786b7ebc4791)

Company: https://www.keypedia.com/companies/ajinomoto-althea-inc/75fb5ea8-b86f-45c1-946e-80c73765f544

Office: https://www.keypedia.com/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd